155 related articles for article (PubMed ID: 30154124)
1. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.
Awada G; Seremet T; Fostier K; Everaert H; Neyns B
Blood Adv; 2018 Aug; 2(16):2156-2158. PubMed ID: 30154124
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.
Héritier S; Jehanne M; Leverger G; Emile JF; Alvarez JC; Haroche J; Donadieu J
JAMA Oncol; 2015 Sep; 1(6):836-8. PubMed ID: 26180941
[No Abstract] [Full Text] [Related]
3. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
4. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
5. Langerhans cell histiocytosis associated with classical Hodgkin lymphoma contains BRAF V600E mutation.
Zhang S; Steinhilber J; Fend F
Ann Hematol; 2019 Jan; 98(1):231-233. PubMed ID: 30003317
[No Abstract] [Full Text] [Related]
6. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
[TBL] [Abstract][Full Text] [Related]
8. A circulating subset of BRAF
Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
[TBL] [Abstract][Full Text] [Related]
9. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
Chapman PB; Solit DB; Rosen N
Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
[TBL] [Abstract][Full Text] [Related]
11. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
12. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
[TBL] [Abstract][Full Text] [Related]
13.
Mastropolo R; Close A; Allen SW; McClain KL; Maurer S; Picarsic J
Blood Adv; 2019 Jun; 3(12):1848-1853. PubMed ID: 31213430
[TBL] [Abstract][Full Text] [Related]
14. Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus.
Chen M; Ding C; Lu T; Niu N; Han B
Ann Hematol; 2018 Jan; 97(1):189-192. PubMed ID: 28889238
[No Abstract] [Full Text] [Related]
15. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
16. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis.
Haroche J; Cohen-Aubart F; Emile JF; Donadieu J; Amoura Z
J Am Acad Dermatol; 2015 Jul; 73(1):e29-30. PubMed ID: 26089069
[No Abstract] [Full Text] [Related]
17. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
[TBL] [Abstract][Full Text] [Related]
18. Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma.
Beland B; Tsang RY; Sutherland G
J Neurooncol; 2018 May; 137(3):667-669. PubMed ID: 29335912
[No Abstract] [Full Text] [Related]
19. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
